Importantly, the regulatory mechanism points to the possibility that SPARC-based gene and protein therapy can be used with current therapeutic modalities to affect tumor regression in advanced colon cancer refractory to therapy and will be a meaningful frame of reference of molecular target therapy of tumor. The gene discussed is SPARC; the disease is neoplasm.